Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

被引：0

作者：

Jung, Sung-Hoon ^{[1
]}

Lee, Je-Jung ^{[2
]}

Kim, Mihee ^{[3
]}

Min, Chang-Ki ^{[4
]}

Lee, Ji Yun ^{[5
]}

Jo, Jae-Cheol ^{[6
]}

Yoon, Sung-Soo ^{[7
]}

Lim, Sung-Nam ^{[8
]}

Do, Young Rok ^{[9
]}

Kim, Kihyun ^{[10
]}

Lee, Jae Hoon ^{[11
]}

Yoo, Kwai Han ^{[11
]}

Bae, Sung Hwa ^{[12
]}

Yi, Jun Ho ^{[13
]}

Jung, Jongheon ^{[14
]}

Eom, Hyeon-Seok ^{[15
]}

机构：

[1] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Sch Med, Hwasun, South Korea

[2] Kyungpook Natl Univ, Dept Hematol Oncol, Sch Med, Kyungpook Natl Univ Hosp, Daegu, South Korea

[3] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea

[4] Seoul St Marys Hosp, Seoul, South Korea

[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

[6] Ulsan Univ Hosp, Ulsan, South Korea

[7] Seoul Natl Univ, Coll Med, Seoul, South Korea

[8] Inje Univ, Coll Med, Haeundae Paik Hosp, Busan, South Korea

[9] Keimyung Univ, Dept Hematooncol, Dongsan Med Ctr, Daegu, South Korea

[10] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea

[11] Gachon Univ, Gil Med Ctr, Seongnam, South Korea

[12] Daegu Catholic Univ Hosp, Daegu, South Korea

[13] Chung Ang Univ Hosp, Seoul, South Korea

[14] Natl Canc Ctr, Goyang, South Korea

[15] Natl Canc Ctr Korea, Dept Internal Med, Goyang, South Korea

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-144

引用

页码：S115 / S115

页数：1

共 50 条

[31] High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.
Rossi, Adriana C.
Monge, Jorge
Niesvizky, Ruben
Hsu, Jing Mei
Shore, Tsiporah
Van Besien, Koen
Pearse, Roger
Mark, Tomer
Jayabalan, David
Mayer, Sebastian Alexander
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32] Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)
Jung, Sung-Hoon
Lee, Je-Jung
Kim, Jin Seok
Min, Chang-Ki
Kim, Kihyun
Choi, Yunsuk
Eom, Hyeon-Seok
Joo, Young Don
Kim, Sung-Hyun
Kwak, Jae-Yong
Kang, Hye Jin
Lee, Jae Hoon
Lee, Ho Sup
Mun, Yeung-Chul
Moon, Joon Ho
Sohn, Sang Kyun
Park, Seong Kyu
Park, Yong
Shin, Ho-Jin
Yoon, Sung-Soo
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (05) : 923 - 929
[33] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
Dunia, D. M.
Dolores, M.
Dolores, S.
Nuria, G.
Miguel, D.
Jaime, A.
Helga, G.
Alejandro, V.
Sonia, H.
Blanca, P.
HAEMATOLOGICA, 2016, 101 : 862 - 862
[34] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
de Miguel, D.
Morales, D.
San Roman, I.
Golbano, N.
Diaz, M.
Arbeteta, J.
Herrero, S.
Subira, D.
PInedo, B.
HAEMATOLOGICA, 2012, 97 : 622 - 622
[35] Feasibility of high dose busulfan and melphalan with autologous hematopoietic stem cell transplantation in multiple myeloma.
Begum, U
Fitzgerald, D
Yong, LO
Grand, M
Thomas, U
Chen, Y
Patel, A
Goodman, D
Dillon, C
Amorosi, E
Cook, P
BLOOD, 1997, 90 (10) : 4346 - 4346
[36] Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma
Desai, A. V.
Heneghan, M. B.
Li, Y.
Bunin, N. J.
Grupp, S. A.
Bagatell, R.
Seif, A. E.
BONE MARROW TRANSPLANTATION, 2016, 51 (09) : 1204 - 1210
[37] Single daily dose of intravenous busulfan and melphalan as conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation
de la Rubia, J.
Lahuerta, J.
Gonzalez, J.
Solano, C.
Rivas, P.
BONE MARROW TRANSPLANTATION, 2007, 39 : S323 - S323
[38] Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma
A V Desai
M B Heneghan
Y Li
N J Bunin
S A Grupp
R Bagatell
A E Seif
Bone Marrow Transplantation, 2016, 51 : 1204 - 1210
[39] HIGH-DOSE MELPHALAN AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HIGH-RISK MYELOMA
HAROUSSEAU, JL
MILPIED, N
GARAND, R
BOURHIS, JH
BRITISH JOURNAL OF HAEMATOLOGY, 1987, 67 (04) : 493 - 493
[40] A PHASE 2 STUDY OF BORTEZOMIB PLUS HIGH-DOSE MELPHALAN CONDITIONING FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN MULTIPLE MYELOMA
Nishihori, T.
Ochoa-Bayona, J. L.
Pidala, J.
Shain, K.
Baz, R.
Simonelli, C. M.
Sullivan, D.
Anasetti, C.
Alsina, M.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S298 - S298

← 1 2 3 4 5 →